SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Gagnon Advisors, LLC

CIK 0001599466 · 1370 AVENUE OF THE AMERICAS, 26TH FLOOR, NEW YORK, NY, 10019 · 212-554-5050

Reported Value
$148M
Q4 2022
Positions
29
Filings on Record
32
2019–present window
Filed
Feb 7, 2023
original filing

Summary

Gagnon Advisors, LLC reported $148M in U.S.-listed holdings across 29 positions for Q4 2022.

Its largest position, Apollo Endosurgery, represents 8.9% of the portfolio.

Compared with Q3 2022, the fund opened 0 new positions and exited 3.

Portfolio Metrics

Turnover
+10.6%
vs prior filed quarter
Top-10 Concentration
+60.0%
share of reported value
Largest Position
+8.9%
Apollo Endosurgery

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $142MQ4 ’18Q1 ’19: $175MQ2 ’19: $175MQ3 ’19: $161MQ4 ’19: $178MQ4 ’19Q1 ’20: $107MQ2 ’20: $139MQ3 ’20: $163MQ4 ’20: $222MQ4 ’20Q1 ’21: $474MQ2 ’21: $263MQ3 ’21: $252MQ4 ’21: $252MQ4 ’21Q1 ’22: $217MQ2 ’22: $165MQ3 ’22: $154MQ4 ’22: $148MQ4 ’22Q1 ’23: $149MQ2 ’23: $149MQ3 ’23: $120MQ4 ’23: $114MQ4 ’23Q1 ’24: $115MQ2 ’24: $131MQ3 ’24: $155MQ4 ’24: $156MQ4 ’24Q1 ’25: $142MQ2 ’25: $149MQ3 ’25: $162MQ4 ’25: $158MQ4 ’25Q1 ’26: $136Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.9%MLP: 6.5%REIT: 3.0%Other: 1.4%Equity WRT: 0.2%
  • Common Stock · 88.9% · $132M
  • MLP · 6.5% · $10M
  • REIT · 3.0% · $4M
  • Other · 1.4% · $2M
  • Equity WRT · 0.2% · $236,288

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
HRTXHERON THERAPUTICS INCSOLD OUT−576.2K0−$2M$0
LUMBER LIQUIDATORS HOLDINGS INCSOLD OUT−307.5K0−$2M$0
WGSWWSEMA4 HOLDINGS CORPSOLD OUT−246.4K0−$56,000$0
ZUORA INCTRIMMED−419.8K411.3K−$4M$3M
SOMALOGIC INCTRIMMED−513.0K513.0K−$2M$1M
ETWOWE2OPEN PARENT HOLDINGSINCTRIMMED−219.5K280.3K−$273,712$236,288
MIROMATRIX MED INCTRIMMED−149.6K229.8K−$974,893$687,107
YEXTYEXT INCTRIMMED−525.5K812.5K−$662,395$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

27 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APOLLO ENDOSURGERY INCCOM8.95%$13M1.33M
2NVGSNAVIGATOR HOLDINGS LTDhistory →SHS7.33%$11M907.5K
3ALAIR LEASE CORPhistory →CL A6.84%$10M263.7K
4EPDENTERPRISE PRODS PARTNERS LPhistory →COM6.51%$10M399.9K
5AMRCAMERESCO INChistory →CL A5.60%$8M145.3K
6NEW RELIC INCCOM5.22%$8M137.0K
7ENVIVA PARTNERS LPCOM UNIT5.15%$8M144.1K
8BLBLACKLINE INChistory →COM4.97%$7M109.5K
9PROFPROFOUND MED CORPhistory →COM NEW4.77%$7M648.5K
10PCRXPACIRA BIOSCIENCEShistory →COM4.70%$7M180.3K
11ETWOWE2OPEN PARENT HOLDINGSINCCOM CL A · W EXP 02/04/20234.49%$7M1.37M
12FIVNFIVE9 INChistory →COM4.34%$6M94.9K
13BLFSBIOLIFE SOLUTIONS INChistory →COM NEW3.75%$6M304.9K
14YEXTYEXT INChistory →CL A3.58%$5M812.5K
15AOSLALPHA AND OMEGA SEMICONDUCTORLTDhistory →SHS3.42%$5M177.6K
16CDNACAREDX INChistory →COM3.38%$5M438.4K
17EQIXEQUINIX INChistory →COM3.03%$4M6.9K
18SECUREWORKS CORPCL A2.55%$4M590.7K
19FRSHFRESHWORKS INChistory →CLASS A COM2.35%$3M236.5K
20EVERBRIDGE INCCOM2.08%$3M104.4K
21ZUORA INCCL A1.77%$3M411.3K
22OPSENS INCCOM1.49%$2M1.63M
23PSIXPOWER SOLUTIONS INTERNATIONALINChistory →COM1.34%$2M659.7K
24CNFINANCE HOLDINGS LIMITEDSPON ADS0.91%$1M784.7K
25SOMALOGIC INCCLASS A COM · W EXP 08/31/20230.90%$1M615.6K
26MIROMATRIX MED INCCOM0.46%$687,107229.8K
27SEMA4 HOLDINGS CORPCOM CL A0.13%$194,974739.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$136M22Apr 22, 202613F-HRchanges · EDGAR ↗
Q4 2025$158M23Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M24Nov 3, 202513F-HRchanges · EDGAR ↗
Q2 2025$149M24Jul 23, 202513F-HRchanges · EDGAR ↗
Q1 2025$142M28May 12, 202513F-HRchanges · EDGAR ↗
Q4 2024$156M26Jan 24, 202513F-HRchanges · EDGAR ↗
Q3 2024$155M27Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$131M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$115M27May 13, 202413F-HRchanges · EDGAR ↗
Q4 2023$114M26Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$120M28Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$149M29Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$149M28Apr 10, 202313F-HRchanges · EDGAR ↗
Q4 2022$148M29Feb 7, 202313F-HRchanges · EDGAR ↗
Q3 2022$154M32Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$165M33Aug 1, 202213F-HRchanges · EDGAR ↗
Q1 2022$217M33May 9, 202213F-HRchanges · EDGAR ↗
Q4 2021$252M34Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$252M35Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$263M32Jul 28, 202113F-HRchanges · EDGAR ↗
Q1 2021$474M30May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$222M29Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$163M30Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$139M26Aug 14, 2020RESTATEMENTchanges · EDGAR ↗
Q1 2020$107M27May 11, 202013F-HRchanges · EDGAR ↗
Q4 2019$178M32Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$161M32Nov 8, 201913F-HRchanges · EDGAR ↗
Q2 2019$175M33Aug 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$175M33May 13, 201913F-HRchanges · EDGAR ↗
Q4 2018$142M31Jan 18, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.